Werewolf Therapeutics to Participate in the Upcoming H.C. Wainwright 27th Annual Global Investment Conference

Core Insights - Werewolf Therapeutics, Inc. is an innovative biopharmaceutical company focused on developing conditionally activated therapeutics to stimulate the immune system for cancer and immune-mediated conditions [3] Group 1: Company Overview - Werewolf Therapeutics is leveraging its proprietary PREDATOR platform to design INDUKINE™ and INDUCER™ molecules that enhance both adaptive and innate immunity [3] - The company's advanced clinical candidates include WTX-124 and WTX-330, which are conditionally activated Interleukin-2 (IL-2) and Interleukin-12 (IL-12) molecules, respectively, aimed at treating solid tumors [3] - WTX-124 is being advanced in multiple tumor types both as a single agent and in combination with immune checkpoint inhibitors, while WTX-330 is also being explored in various solid tumor types [3] Group 2: Upcoming Events - Daniel J. Hicklin, Ph.D., President and CEO, and Randi Isaacs, M.D., Chief Medical Officer, will participate in a fireside chat at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025 [1] - A live webcast of the presentation will be available, with an archived replay accessible for approximately 90 days post-event [2]